Satellos Bioscience Inc.

MSCLF

OTC

Healthcare

Medical - Pharmaceuticals

Toronto, ON, CA14 employeessatellos.com

—

At a Glance

AI-generated

Satellos Bioscience Inc.

6-K

Satellos Bioscience Inc. reported its 2025 financial results, including a net loss of $24.9 million, and highlighted clinical progress for SAT-3247 with the initiation of the BASECAMP Phase 2 pediatric trial and continued data from the TRAILHEAD adult study. The company completed a $57.2 million equity financing in February 2026, extending its cash runway through 2027.

—

Market Cap

—

Revenue

—

Net Income

Employees14

Fundamentals

How The Business Makes Money

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Industry Medical - Pharmaceuticals

Activity

What Changed Recently

Securities Issuance

Mar 26, 2026

Current Report on Form 6-K

Securities Issuance

Mar 9, 2026

Current Report on Form 6-K

Securities Issuance

Feb 23, 2026

Current Report on Form 6-K

Securities Issuance

Feb 18, 2026

Current Report on Form 6-K

Securities Issuance

Feb 17, 2026

Current Report on Form 6-K

Peer Companies

Company	Price	Change	Market Cap	P/E
KNTPFKintor Pharmaceutical Lim...	—	—	—	—
PBIGFParadigm Biopharmaceutica...	—	—	—	—
SPHRYStarpharma Holdings Limit...	—	—	—	—
TOKIFTOKIF	—	—	—	—
POLBFPoolbeg Pharma PLC	—	—	—	—
VSBCVitaSpring Biomedical Co....	—	—	—	—
IUGNFImugene Limited	—	—	—	—
BSEMBioStem Technologies, Inc...	—	—	—	—

Analyst View

Company Profile

CIK0001421642

ISINCA80401L3083

AddressRoyal Bank Plaza, Toronto, ON, M5J 2J1, CA

SEC EDGAR